Sorafenib for the treatment of advanced hepatocellular carcinoma.

Health technology assessment (Winchester, England)

Volumn 14 Suppl 1, Issue , 2010, Pages 17-21

  Connock, M ^a   Round, J ^b   Bayliss, S ^b   Tubeuf, S ^b   Greenheld, W ^b   Moore, D ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE; SORAFENIB;

COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; QUALITY OF LIFE; REVIEW; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; LIVER NEOPLASMS; MODELS, ECONOMIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84886943205     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl1/03     Document Type: Review

References (24)